New evidence for teriflunomide in multiple sclerosis

Affiliations

¹ Department of Neurology, Medical Faculty, Heinrich-Heine-University, D-40225 Düsseldorf, Germany. Electronic address: bernd.kieseier@uni-duesseldorf.de.
² Department of Neurology, Westfälische-Wilhelms-University, Münster, Germany.

Comment

Bernd C Kieseier et al. Lancet Neurol. 2014 Mar.

. 2014 Mar;13(3):234-5.

doi: 10.1016/S1474-4422(14)70012-2. Epub 2014 Jan 23.

¹ Department of Neurology, Medical Faculty, Heinrich-Heine-University, D-40225 Düsseldorf, Germany. Electronic address: bernd.kieseier@uni-duesseldorf.de.
² Department of Neurology, Westfälische-Wilhelms-University, Münster, Germany.

No abstract available

Comment on

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L; TOWER Trial Group. Confavreux C, et al. Lancet Neurol. 2014 Mar;13(3):247-56. doi: 10.1016/S1474-4422(13)70308-9. Epub 2014 Jan 23. Lancet Neurol. 2014. PMID: 24461574 Clinical Trial.